TCTR20210517006招募中2 期
Immunogenicity and the safety of the COVID-19 vaccines available in Thailand.
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 3,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 N/A (No limit)（—）
- 性别
- All
入选标准
- •1. 18 years old or more
- •2. negative for blood SARS-CoV-2 antibody
- •3. negative for nasopharynx PCR for SARS-CoV-2
- •4. Negative urine pregnancy test (in case of potential of pregnancy)
- •5. No history of a severe allergic reaction to the prior vaccine.
- •6. No fever nor history of fever within 14 days.
- •7. No symptom of respiratory tract infection within 14 days.
- •8. ECOG 0,1
- •9. sign informed consent to the study.
排除标准
- •1. prior COVID-19 vaccination.
- •2. Vaccination with any vaccines within 30 days
- •3. administration of steroid or receive immunoglobulins within 30 days
- •4. Receive immunosuppression agent within 30 days.
- •5. pregnancy.
- •6. lactation.
- •7. acute coronary syndrome in the past year.
- •8. Acute stroke in the past year.
- •9. Splenectomy
- •10. active chronic infectious disease.
研究者
相似试验
已完成
不适用
Safety and humoral immunogenicity of COVID-19 vaccine against SAR-CoV2 wild type and Omicron variant in patients with solid cancerSolid cancerCOVID-19CarcinomaCOVID-19 VaccinesSarcomaTCTR20230510001Faculty of Medicine, Chiang Mai University110
已完成
1 期
Safety and Immunogenicity of EXG-5003.Prevention for SARS-CoV-2 infection diseaseJPRN-jRCT2041210013Doi Yohei60
已完成
不适用
Immunogenicity and safety of SARS-CoV-2 (COVID-19 virus) vaccine in liver transplant recipientsImmunogenicity and safety of SARS-CoV-2 vaccine in liver transplant recipientsliver transplant, vaccine, COVID-19, SARS-CoV-2, safetyTCTR20210526004Faculty of medicine, Chulalongkorn university60
尚未招募
不适用
Immunogenicity and safety of SARS-CoV-2 (COVID-19 virus) vaccine in patients with hepatocellular carcinomaImmunogenicity and safety of SARS-CoV-2 vaccine in patients with hepatocellular carcinomaCOVID-19, vaccine, hepatocellular carcinoma, SARS-CoV-2TCTR20210525005Faculty of Medicine, Chulalongkorn university60
进行中（未招募）
1 期
A study to Evaluate Immunogenicity, Safety and Tolerability of a Single Dose of ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2COVID-19 diseaseMedDRA version: 23.1Level: PTClassification code 10084457Term: COVID-19 immunisationSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2021-005504-36-BEBavarian Nordic A/S4,000